Zhang Yu, Wang Kefan, Zhou Lijing, Guo Nan, Chen Qingyou, Zhai Yuanyuan
Yu Zhang, Department of Electrophysiology, Third Affiliated Hospital of Qiqihar Medical College, 27 Taishun Street, Qiqihar, Heilongjiang Province 161000, P.R. China.
Kefan Wang, Department of Electrophysiology, Third Affiliated Hospital of Qiqihar Medical College, 27 Taishun Street, Qiqihar, Heilongjiang Province 161000, P.R. China.
Pak J Med Sci. 2025 May;41(5):1274-1279. doi: 10.12669/pjms.41.5.11520.
To compare the efficacy of drug-coated balloons (DCB) and bare metal stents (BMS) in treating lower extremity arteriosclerosis obliterans (LEASO).
Clinical data of 83 patients who underwent LEASO angioplasty with DCB or BMS at the Third Affiliated Hospital of Qiqihar Medical College from July 2021 to January 2024 were retrospectively analyzed. Patients were divided into the DCB (n=43) and BMS (n=40) groups based on the treatment method. Changes in ankle-brachial index (ABI), pulse volume recording (PVR), vascular endothelial function indicators, incidence of complications, and patency rate were compared between the two groups.
Three months after the surgery, the ABI and nitric oxide (NO) levels in the DCB group were higher, while the upstroke time (UT), percentage of mean arterial pressure (%MAP), brachial-ankle pulse wave velocity (baPWV), and endothelin-1 (ET-1) levels were lower than those in the BMS group (P<0.05). There was no significant difference in the incidence of complications between the two groups (P>0.05). One year after the surgery, the patency rate of the DCB group was higher than that of the BMS group (P<0.05).
DCB treatment for LEASO is superior to BMS in improving vascular function, protecting endothelial function, and achieving a one-year patency rate.
比较药物涂层球囊（DCB）与裸金属支架（BMS）治疗下肢动脉硬化闭塞症（LEASO）的疗效。
回顾性分析2021年7月至2024年1月在齐齐哈尔医学院附属第三医院接受DCB或BMS治疗LEASO血管成形术的83例患者的临床资料。根据治疗方法将患者分为DCB组（n = 43）和BMS组（n = 40）。比较两组患者的踝肱指数（ABI）、脉搏容积记录（PVR）、血管内皮功能指标、并发症发生率和通畅率的变化。
术后3个月，DCB组的ABI和一氧化氮（NO）水平较高，而上肢上升时间（UT）、平均动脉压百分比（%MAP）、臂踝脉搏波速度（baPWV）和内皮素-1（ET-1）水平低于BMS组（P<0.05）。两组并发症发生率比较，差异无统计学意义（P>0.05）。术后1年，DCB组的通畅率高于BMS组（P<0.05）。
DCB治疗LEASO在改善血管功能、保护内皮功能和实现1年通畅率方面优于BMS。
